liver
second
largest
organ
bodi
multitud
function
includ
carbohydr
fatti
acid
metabol
lipid
transport
protein
synthesi
storag
fatsolubl
vitamin
well
detoxif
modif
compound
absorb
small
intestin
dual
blood
suppli
approxim
come
portal
vein
hepat
arteri
primari
function
unit
liver
hepat
lobul
consist
hexagon
zone
hepat
parenchyma
surround
central
hepat
vein
number
portal
tract
peripheri
contain
termin
portal
vein
bile
ductul
hepat
arteriol
normal
liver
blood
flow
portal
venou
branch
specialis
vascular
channel
call
hepat
sinusoid
centrilobular
hepat
vein
hepat
sinusoid
lack
distinct
basement
membran
endotheli
cell
fenestr
permit
bidirect
free
passag
solut
sinusoid
subsinusoid
space
known
space
diss
hepatocyt
account
liver
mass
cell
microvilli
basolater
surfac
facilit
interchang
nutrient
sinusoid
respons
metabol
synthet
function
liver
chronic
liver
diseas
disturb
normal
structur
function
liver
initi
hepat
fibrosi
process
eventu
lead
progress
destruct
normal
hepat
architectur
loss
function
hepatocyt
develop
liver
cirrhosi
angiotensin
ii
main
effector
peptid
reninangiotensin
system
ra
known
play
import
role
chronic
tissu
injuri
fibrosi
cardiovascular
diseas
chronic
renal
diseas
diabet
role
liver
diseas
less
well
establish
howev
recent
studi
indic
organ
reninangiotensinsystem
within
liver
local
gener
angiotensin
ii
play
import
role
pathogenesi
liver
injuri
hepat
fibrosi
also
evid
fibrot
liver
angiotensin
ii
contribut
portal
hypertens
stimul
contract
perisinusoid
myofibroblast
increas
sinusoid
resist
portal
flow
addit
local
effect
liver
system
ra
activ
patient
advanc
liver
diseas
respons
mesenter
system
vasodilat
import
homeostat
role
maintain
adequ
perfus
pressur
kidney
vital
organ
also
contribut
renal
sodium
water
retent
releas
aldosteron
stimul
secret
antidiuret
hormon
adh
posterior
pituitari
multipl
role
ra
liver
diseas
lead
major
interest
potenti
role
ra
antagonist
prevent
liver
fibrosi
treatment
chronic
liver
diseas
complic
larg
number
chronic
liver
diseas
caus
hepat
fibrosi
includ
chronic
viral
hepat
alcohol
liver
diseas
nonalcohol
fatti
liver
diseas
iron
overload
diseas
biliari
tract
immun
metabol
liver
diseas
cirrhosi
end
stage
hepat
fibrosi
characteris
presenc
extens
fibrot
septa
separ
surround
parenchym
nodul
regener
hepatocyt
disturb
normal
hepat
architectur
conjunct
vasoconstrict
within
liver
imped
portal
blood
flow
caus
portal
hypertens
caus
mani
seriou
complic
cirrhosi
includ
varic
bleed
hepat
encephalopathi
ascit
hepat
b
infect
common
caus
cirrhosi
worldwid
also
singl
import
caus
hepatocellular
carcinoma
diseas
respons
nearli
one
third
world
cancerrel
death
lodato
et
al
current
proven
treatment
hepat
fibrosi
remov
respons
injuri
agent
recent
studi
shown
achiev
exampl
elimin
viral
replic
patient
chronic
hepat
b
c
hepat
fibrosi
even
earli
stage
cirrhosi
resolv
patient
endstag
cirrhosi
liver
failur
therapi
limit
symptom
control
prevent
life
threaten
complic
varic
bleed
whilst
cure
achiev
liver
transplant
unfortun
despit
major
advanc
antivir
therapi
recent
year
mani
patient
chronic
hepat
respond
therapi
also
number
chronic
liver
diseas
current
effect
treatment
therefor
ongo
need
develop
antifibrot
therapi
use
prevent
fibrosi
progress
develop
cirrhosi
healthi
liver
extracellular
matrix
ecm
consist
collagen
predominantli
type
iv
glycoprotein
proteoglycan
glycosaminoglycan
provid
structur
function
framework
cellular
migrat
adhes
differenti
prolifer
fibrogen
activ
schuppan
et
al
space
diss
contain
delic
ecm
basement
membranelik
composit
permit
solut
diffus
blood
within
sinusoid
surround
cell
hepat
fibrosi
result
major
chang
volum
composit
ecm
increas
interstiti
fibrillar
collagen
type
iii
well
nonfibrillar
collagen
type
iv
vi
proteoglycan
glycosaminoglycan
content
also
increas
overal
composit
ecm
chang
lowdens
form
denser
complex
interstiti
type
collagen
noncollagen
ecm
content
liver
increas
least
fold
cirrhot
liver
associ
loss
hepatocyt
microvilli
structur
chang
sinusoid
endothelium
includ
loss
fenestr
deposit
fibrillar
collagen
space
diss
chang
impair
transfer
sinusoid
nutrient
hepatocyt
facilit
hepatocyt
injuri
liver
dysfunct
pattern
liver
fibrosi
ultim
depend
site
intens
injuri
henc
biliari
obstruct
result
bile
ductular
periductular
myofibroblast
prolifer
initi
produc
periport
link
portalport
fibrosi
viral
hepat
infect
lead
portal
portalcentr
fibrosi
whilst
disrupt
hepat
venou
outflow
occur
right
ventricular
failur
budd
chiari
syndrom
caus
centrolobular
hepatocyt
necrosi
lead
centrolobular
fibrosi
central
central
septa
cassiman
roskam
cell
type
involv
hepat
fibrosi
studi
hepat
stellat
cell
hsc
part
due
rel
eas
cell
isol
purifi
subcultur
human
anim
liver
tissu
howev
becom
clear
characteris
cellular
marker
electron
microscop
studi
divers
popul
myofibroblast
within
liver
may
also
contribut
hepat
fibrosi
includ
portal
septal
myofibroblast
cell
resid
vessel
wall
centrilobular
myofibroblast
even
marrowderiv
hsc
myofibroblast
cassiman
kalli
alison
forb
russo
et
al
like
express
import
myofibroblast
subtyp
vari
differ
human
diseas
anim
model
hsc
normal
resid
space
diss
respons
storag
vitamin
maintain
quiescent
nonfibrogen
phenotyp
part
surround
ecm
compos
predominantli
collagen
iv
collagen
type
present
within
lamina
densa
basal
lamina
noncollagen
compon
laminin
follow
repetit
injuri
chang
composit
ecm
conjunct
releas
proinflammatori
profibrot
cytokin
releas
damag
hepatocyt
kuppfer
cell
inflammatori
cell
lead
cascad
event
culmin
transform
hsc
activ
myofibroblast
activ
cell
deposit
extracellular
matrix
ecm
addit
express
contractil
protein
enabl
modul
sinusoid
blood
flow
hsc
capabl
produc
broad
array
profibrot
proinflammatori
cytokin
chemokin
includ
tansform
growth
factor
tgf
platelet
deriv
growth
factor
pdgf
angiotensin
ii
act
paracrin
autocrin
manner
perpetu
fibrosi
friedman
maher
bissel
discuss
recent
data
shown
angiotensin
ii
involv
recruit
inflammatori
cell
respons
liver
injuri
sewnath
et
al
transform
hepat
stellat
cell
activ
phenotyp
hepat
fibrosi
dynam
process
end
result
reflect
balanc
pathway
lead
matrix
accumul
result
matrix
degrad
fibrosi
resolut
matrix
metalloproteinas
mmp
capabl
enzymat
degrad
ecm
secret
mani
liver
cell
includ
hsc
kuppfer
cell
hepatocyt
macrophag
knittel
et
al
certain
mmp
may
contribut
pathogenesi
fibrosi
facilit
liver
remodel
alter
quantiti
composit
ecm
mmp
subtyp
degrad
fibrillar
collagen
fibrot
liver
therefor
drive
fibrosi
resolut
counterbalanc
effect
mmp
group
tissu
inhibitor
metalloproteinas
timp
promot
collagen
matrix
deposit
prevent
ecm
degrad
matrix
proteinas
arthur
sinc
discoveri
renin
kidney
extract
tigerstedt
bergman
understand
intricaci
organis
function
reninangiotensin
system
ra
expand
consider
tigerstedt
r
basso
terragno
circul
ra
best
known
role
regul
blood
pressur
fluid
electrolyt
homeostasi
angiotensin
ii
princip
effector
ra
caus
vasoconstrict
directli
stimul
angiotensin
type
receptor
present
surfac
vascular
smooth
muscl
cell
indirectli
potenti
releas
norepinephrin
postganglion
sympathet
fibr
stimul
antidiuret
hormon
adh
releas
posterior
pituitari
longterm
angiotensin
ii
regul
blood
pressur
modul
sodium
water
reabsorpt
stimul
receptor
kidney
stimul
product
releas
aldosteron
adren
gland
addit
angiotensin
ii
increas
thirst
sensat
stimul
subforn
organ
within
diencephalon
effect
may
import
chronic
organ
damag
includ
promot
thrombosi
cardiac
hypertrophi
angiogenesi
classic
enzymat
pathway
gener
angiotensin
ii
begin
cleavag
peptid
bond
leucin
valin
residu
angiotensinogen
produc
biolog
inact
decapeptid
angiotensin
process
mediat
renin
aspart
proteas
releas
juxtaglomerular
cell
kidney
circul
cascad
continu
angiotensin
convert
enzym
ace
found
predominantli
capillari
lung
cleav
dipeptid
cterminu
angiotensin
form
angiotensin
ii
action
angiotensin
ii
mediat
via
specif
seven
transmembran
g
proteincoupl
receptor
human
two
angiotensin
receptor
differ
affin
angiotensin
ii
describ
angiotensin
ii
cleav
either
carboxyor
aminoterminu
produc
biolog
activ
angiotensin
fragment
thu
aminoterminu
angiotensin
iii
form
follow
cleavag
aspartatearginin
bond
angiotensin
ii
aminopeptidas
angiotensin
iv
form
follow
cleavag
angiotensin
iii
aminopeptidas
b
n
ardail
angiotensin
iii
share
mani
properti
angiotensin
ii
pressor
activ
aldosteron
stimul
activ
angiotensin
ii
angiotensin
iv
distinct
receptor
central
nervou
system
effect
togeth
oppos
action
angiotensin
ii
von
bohlen
und
halbach
enzymat
cleavag
carboxyterminu
angiotensin
ii
angiotensin
produc
biolog
activ
fragment
angiotensin
renew
interest
circul
ra
follow
simultan
discoveri
two
independ
research
group
ace
homologu
call
two
enzym
share
protein
sequenc
similar
distinct
enzymat
action
tissu
distribut
donoghu
et
al
tipni
et
al
like
ace
zinc
metalloproteas
type
integr
membran
protein
express
predominantli
cell
surfac
act
ectoenzym
membran
bound
form
compris
extracellular
ntermin
domain
contain
activ
site
short
intracellular
ctermin
anchor
highest
level
seen
kidney
heart
testi
gastrointestin
tract
particularli
ileum
duodenum
jejunum
caecum
colon
lower
level
express
liver
lung
harmer
et
al
ham
et
al
donoghu
tipni
releas
cell
surfac
action
secretaselik
enzym
solubl
form
detect
plasma
urin
lew
et
al
ocaranza
et
al
rice
et
al
contrast
ace
contain
singl
catalyt
domain
compar
two
activ
site
nand
cdomain
somat
ace
furthermor
carboxypeptidas
rather
peptidyl
dipeptidas
consequ
mechan
action
differ
substrat
specif
ace
warner
et
al
also
inhibit
invitro
ace
inhibitor
captopril
lisinopril
enalaprilat
tipni
activ
number
biolog
activ
peptid
includ
angiotensin
angiotensin
ii
de
arg
bradykinin
apellin
dynorphin
vicker
et
al
enzym
prefer
hydrophob
basic
residu
carboxyterminu
well
propyl
residu
penultim
posit
tabl
turner
mani
divers
function
interact
realis
burrel
et
al
thoma
enzym
crucial
cardiovascular
renal
injuri
also
identifi
receptor
sar
coronaviru
w
particular
interest
past
year
role
format
biolog
activ
fragment
angiotensin
gener
angiotensin
directli
enzymat
cleavag
angiotensin
ii
indirectli
cleav
angiotensin
inact
peptid
fragment
angiotensin
enzymat
cleav
ace
angiotensin
two
pathway
convers
angiotensin
ii
angiotensin
kinet
favour
invitro
vicker
rice
et
al
furthermor
invitro
studi
show
potent
hydrolys
angiotensin
ii
angiotensin
propyl
endopeptidas
propyl
carboxypeptidas
peptidas
similar
carboxypeptidas
action
ferrario
find
suggest
major
angiotensin
gener
enzym
well
import
enzym
degrad
angiotensin
ii
biolog
effect
angiotensin
first
describ
rat
hypothalamichypophysi
implant
angiotensin
stimul
releas
vasopressin
schiavon
et
al
subsequ
anim
experi
shown
angiotensin
antihypertens
benter
et
al
antiarrhythm
ferreira
santo
almeida
cardioprotect
properti
ferreira
santo
almeida
vasodilatori
effect
angiotensin
mediat
releas
nitric
oxid
nakamoto
et
al
p
li
et
al
brosnihan
li
ferrario
prostaglandin
freeman
et
al
iyer
et
al
releas
interact
bradykinin
p
li
gorelik
carbini
scicli
fernand
et
al
ueda
et
al
angiotensin
also
shown
antitroph
properti
vascular
endotheli
smooth
muscl
cell
cardiac
myocyt
cardiac
fibroblast
freeman
strawn
ferrario
tallant
iwata
et
al
tallant
ferrario
gallagh
addit
antiinflammatori
antifibrot
grobe
et
al
grobe
et
al
antithrombot
properti
kucharewicz
et
al
kucharewicz
et
al
attribut
angiotensin
put
receptor
angiotensin
g
proteincoupl
receptor
encod
ma
protooncogen
santo
et
al
receptor
shown
invitro
heterooligomer
receptor
act
physiolog
antagonist
angiotensin
ii
well
interact
receptor
castro
et
al
kosteni
et
al
evid
emerg
receptor
yet
unidentifi
angiotensin
receptor
subtyp
may
import
biolog
action
angiotensin
walter
gaspari
widdop
silva
et
al
action
angiotensin
clearli
oppos
angiotensin
ii
consequ
propos
ra
divid
basi
two
distinct
arm
capabl
produc
complementari
effect
fig
thu
conceptu
understand
ra
evolv
endocrin
system
consist
linear
sequenc
enzymat
reaction
yield
effector
peptid
angiotensin
ii
complex
system
close
integr
system
kininkallikrein
system
potenti
produc
effector
peptid
counterbalanc
effect
angiotensin
angiotensin
ii
importantli
ra
system
endocrin
system
also
function
autonom
paracrin
system
within
certain
organ
local
intraorgan
reninangiotensin
system
describ
number
organ
includ
heart
kidney
liver
pancrea
batal
leung
chappel
local
system
shown
respons
variou
stimuli
physiolog
pathophysiolog
import
moreov
local
gener
angiotensin
peptid
fragment
plethora
action
figur
reninangiotensin
system
peptid
shown
blue
box
enzym
yellow
box
target
receptor
pink
box
system
four
known
biolog
activ
peptid
angiotensin
ii
iii
iv
angiotensin
act
distinct
cellular
receptor
ma
two
princip
arm
system
act
via
ma
receptor
oppos
action
implic
cell
growth
antiprolifer
apoptosi
reactiv
oxygen
speci
gener
hormon
secret
proinflammatori
profibrogen
action
role
hepat
ra
normal
diseas
liver
less
well
describ
heart
kidney
howev
clear
key
compon
enzymat
cascad
lead
format
angiotensin
ii
organ
present
liver
one
common
theme
throughout
literatur
observ
liver
injuri
associ
upregul
andor
redistribut
ra
compon
includ
angiotensinogen
renin
ace
angiotensin
ii
receptor
sakata
et
al
paizi
et
al
main
sourc
ra
precursor
angiotensinogen
hepatocyt
morri
iwamoto
reid
paizi
low
level
protein
also
detect
kupffer
cell
bile
duct
epithelium
sawa
studi
human
rodent
show
plasma
renin
concentr
activ
substrat
angiotensinogen
increas
cirrhot
liver
compar
control
morri
richoux
et
al
kojima
et
al
rinconsanchez
et
al
riverahuizar
et
al
product
angiotensiogen
cleavag
renin
angiotensin
demonstr
liver
tissu
howev
evid
suggest
de
novo
gener
angiotensin
may
occur
local
hepatomesenter
vascular
bed
well
circul
plasma
admira
et
al
contrast
angiotensin
ii
present
plasma
liver
tissu
normal
anim
increas
significantli
rat
model
liver
diseas
cirrhot
patient
asbert
et
al
wang
et
al
herath
et
al
ra
compon
express
normal
liver
tissu
includ
ace
receptor
predominantli
localis
vascular
endothelia
also
observ
hepatocyt
bile
duct
epitheli
cell
h
ikura
et
al
fibrot
liver
ace
protein
express
also
found
fibrou
septa
mesenchym
cell
hepat
stellat
cell
myofibroblast
kupffer
cell
h
paizi
ikura
although
receptor
abund
liver
express
receptor
gene
low
detect
normal
diseas
liver
paizi
nabeshima
et
al
report
far
attribut
receptor
gene
express
particular
liver
cell
type
batal
cowork
detect
low
level
receptor
messeng
rna
isol
human
hepatocyt
hsc
phenotyp
quiescent
cultur
activ
vivo
activ
despit
possibl
exist
receptor
liver
recent
studi
show
ablat
receptor
augment
liver
injuri
fibrosi
nabeshima
vast
major
report
support
concept
receptor
mediat
inflammatori
prolif
vascular
effect
angiotensin
ii
liver
kanno
tazuma
chayama
yoshiji
et
al
moreov
gene
express
human
myofibroblast
shown
correl
extent
fibrosi
degre
portal
hypertens
ikura
increas
evid
liver
angiotensin
ii
regul
cell
growth
fibrosi
involv
key
event
inflamm
wound
heal
one
cell
type
pivot
process
activ
hepat
stellat
cell
follow
injuri
express
receptor
increas
activ
hepat
stellat
cell
cell
demonstr
increas
respons
angiotensin
ii
compar
quiescent
hsc
batal
et
al
incub
activ
hsc
angiotensin
ii
result
dose
depend
increas
intracellular
calcium
concentr
cell
contract
cellular
prolifer
mitogenactiv
protein
kinas
mapk
depend
pathway
effect
block
losartan
angiotensin
ii
type
receptor
antagonist
arb
batal
arb
block
dose
depend
profibrot
proinflammatori
effect
angiotensin
ii
hsc
includ
express
inflammatori
cytokin
growth
factor
ctgf
nf
product
extracellular
matrix
ecm
fibrot
marker
smooth
muscl
actin
collagen
h
ohishi
et
al
kurikawa
et
al
j
zhang
et
al
angiotensin
ii
also
power
chemoattract
activ
hsc
concentr
cell
site
hepat
injuri
effect
may
amplifi
upregul
key
compon
local
ra
liver
injuri
paizi
creat
autocrin
loop
liver
injuri
increas
angiotensin
ii
product
turn
perpetu
liver
damag
fibrosi
recent
studi
show
profibrogen
effect
angiotensin
ii
human
hepat
stellat
cell
least
part
mediat
via
gener
reactiv
oxygen
speci
ro
nadph
oxidas
propos
mechan
support
find
hepat
fibrosi
follow
bile
duct
ligat
markedli
attenu
nadph
oxidasedefici
mice
nadph
oxidas
express
hepat
cell
type
includ
kupffer
cell
sinusoid
endotheli
cell
cell
may
also
contribut
fibrogenesi
format
ro
whalen
et
al
import
ra
hepat
fibrosi
support
studi
shown
inflamm
fibrosi
respons
treatment
kanno
bile
duct
ligat
attenu
knockout
mice
support
evid
also
come
invivo
studi
shown
angiotensin
ii
infus
stimul
prolifer
bile
duct
cell
exacerb
liver
fibrosi
increas
serum
transaminas
endotoxin
level
bdl
rat
liver
interestingli
angiotensin
ii
infus
increas
number
vascular
thrombos
small
hepat
vessel
within
portal
tract
bdl
sham
oper
anim
put
mechan
increas
tissu
factor
procoagul
activ
prothrombot
effect
angiotensin
ii
may
contribut
liver
injuri
collagen
deposit
caus
local
hypoxia
corpechot
et
al
addit
direct
profibrot
effect
angiotensin
ii
amplifi
gener
inflammatori
respons
chronic
liver
injuri
induc
acut
phase
reactant
oxid
stress
releas
inflammatori
fibrogen
cytokin
tgf
tnf
ecm
deposit
miyoshi
et
al
sasaki
et
al
addit
complex
interact
cell
type
angiotensin
ii
induc
secret
monocyt
chemoattract
protein
activ
hsc
marra
et
al
kanno
et
al
low
molecular
weight
secretori
protein
potent
stimul
leukocyt
recruit
activ
upregul
gene
express
though
mediat
via
rho
intracellular
signal
pathway
follow
angiotensin
ii
bind
receptor
kanno
event
occur
result
receptor
activ
includ
releas
number
transcript
factor
activ
protein
signal
transduc
activ
transcript
stat
nf
b
jamaluddin
et
al
mcallisterluca
et
al
crucial
mani
downstream
proinflammatori
effect
angiotensin
ii
product
cytokin
furthermor
activ
transcript
factor
nf
b
fundament
posit
feedback
mechan
angiotensin
ii
act
receptor
locat
hepatocyt
stimul
transcript
angiotensinogen
precursor
angiotensin
ron
brasier
haben
brasier
li
copland
number
cell
type
present
within
liver
express
receptor
may
contribut
proinflammatori
effect
angii
exampl
kupffer
cell
resid
hepat
macrophag
activ
alcohol
liver
diseas
stimul
angiotensin
ii
produc
tnfand
enomoto
et
al
product
cytokin
kuppfer
cell
significantli
reduc
angiotensin
receptor
antagonist
arb
losartan
ace
inhibitor
captopril
confirm
role
receptor
cell
type
h
wei
jun
qiang
hepat
ra
also
appear
affect
balanc
ecm
deposit
degrad
depend
rel
activ
matrix
metalloproteinas
mmp
inhibitor
tissu
inhibitor
metalloproteinas
timp
broad
specif
inhibitor
mmp
act
form
complex
mmp
angiotensin
ii
upregul
mrna
express
activ
hsc
receptor
bind
subsequ
protein
kinas
c
pkc
intracellular
signal
pathway
verifi
two
anim
model
fibrosi
pig
serum
ccl
downregul
gene
express
follow
administr
ace
inhibitor
arb
yoshiji
paizi
et
al
recent
demonstr
gene
express
protein
level
markedli
elev
bdl
liver
cirrhot
human
liver
tissu
open
possibl
put
counterregulatori
arm
ra
activ
involv
chronic
liver
diseas
paizi
et
al
addit
angiotensin
ma
recent
shown
increas
progress
follow
bile
duct
ligat
rat
herath
lubel
et
al
pereira
et
al
furthermor
model
pharmacolog
blockad
ma
receptor
may
worsen
liver
fibrosi
pereira
potenti
benefit
angiotensin
particular
clinic
relev
ace
inhibitor
angiotensin
receptor
blocker
arb
result
elev
angiotensin
rais
possibl
benefici
effect
drug
mediat
peptid
iyer
ferrario
chappel
collist
hendel
ace
inhibitor
found
multipl
benefit
cardiovascular
renal
diseas
hypertens
prevent
myocardi
infarct
stroke
prevent
heart
failur
arrhythmia
renal
failur
proteinuria
diabet
nephropathi
losartan
first
drug
altern
class
ra
antagonist
block
angiotensin
ii
type
receptor
subsequ
larg
number
ace
inhibitor
angiotensin
receptor
blocker
arb
develop
two
class
drug
collect
shown
reduc
chronic
endorgan
damag
cardiovascular
renal
diseas
diabet
benefit
drug
appear
independ
antihypertens
effect
suggest
direct
antifibrot
tissu
protect
effect
diseas
intervent
anim
studi
use
ra
inhibitor
provid
compel
evid
ra
play
major
role
pathogenesi
hepat
fibrosi
studi
perform
rodent
sever
establish
model
hepat
fibrosi
use
tabl
ramo
et
al
h
wei
et
al
jonsson
et
al
ohishi
paizi
et
al
croquet
et
al
ramalho
et
al
toblli
et
al
kurikawa
tuncer
et
al
yoshiji
x
li
et
al
h
wei
although
methodolog
differ
wide
surpris
degre
uniform
result
almost
publish
studi
ace
inhibitor
receptor
blocker
shown
benefici
effect
includ
attenu
fibrosi
downregul
key
inflammatori
profibrot
cytokin
known
involv
pathogenesi
hepat
fibrosi
summari
major
find
studi
provid
tabl
one
common
seriou
complic
cirrhosi
develop
hepatocellular
carcinoma
keep
known
prolif
angiogen
effect
angiotensin
ii
increas
evid
ra
involv
develop
growth
neoplasm
experi
mice
shown
potent
angiogen
factor
vascular
endotheli
growth
factor
vegf
induc
angiotensin
ii
ace
inhibitor
perindopril
significantli
attenu
vegfmedi
tumour
develop
efficaci
eas
use
excel
safeti
profil
ra
blocker
treatment
patient
cardiovascular
renal
diseas
make
attract
potenti
therapi
treatment
human
liver
diseas
effect
blockad
portal
hypertens
examin
number
studi
rational
studi
angiotensin
ii
increas
intra
hepat
resist
portal
flow
cirrhot
liver
mediat
contract
perisinusoid
myofibroblast
thu
contribut
variabl
compon
portal
hypertens
vlachogiannako
et
al
although
studi
shown
drug
lower
portal
pressur
use
associ
unaccept
drop
system
blood
pressur
renal
blood
flow
particularli
patient
advanc
liver
diseas
system
renin
angiotensin
system
activ
patient
respons
system
mesenter
vasodil
arroyo
et
al
bosch
et
al
sakata
play
central
role
mainten
renal
perfus
pressur
glomerular
filtrat
small
number
studi
examin
effect
ra
inhibit
fibrosi
human
liver
diseas
larg
randomis
trial
may
first
seem
surpris
consid
wealth
support
evid
come
anim
invitro
studi
howev
studi
antifibrogen
therapi
difficult
perform
man
need
perform
multipl
biopsi
addit
fibrosi
progress
slowli
common
diseas
hepat
c
nonalcohol
fatti
liver
diseas
make
difficult
detect
possibl
benefici
effect
antifibrot
therapi
unless
studi
conduct
number
year
one
small
studi
found
administr
angiotensin
ii
receptor
antagonist
losartan
week
patient
nonalcohol
steatohepat
nash
reduc
serum
tgf
ferritin
aminotransferas
five
patient
show
improv
grade
hepat
necroinflamm
importantli
small
studi
control
group
analys
intent
treat
basi
yokohama
et
al
subsequ
studi
pre
post
treatment
biopsi
seven
patient
nonalcohol
steatohepat
treat
losartan
week
compar
eight
patient
nonalcohol
fatti
liver
diseas
act
control
group
treatment
group
show
signific
improv
necroinflammatori
grade
stage
fibrosi
significantli
fewer
activ
hsc
mild
increas
quiescent
hsc
yokohama
et
al
end
howev
lack
proper
randomis
control
group
particular
problem
studi
patient
nash
sinc
diseas
improv
respons
chang
life
style
number
studi
report
possibl
antifibrot
effect
ra
blocker
patient
hepat
c
one
studi
hcv
infect
patient
mild
fibrosi
treat
losartan
ursodeoxychol
acid
whilst
control
receiv
ursodeoxychol
acid
alon
signific
differ
serum
marker
hepat
fibrosi
type
iv
collagen
losartan
ursodeoxychol
acid
group
signific
chang
fibrosi
score
metavir
score
system
observ
full
detail
studi
publish
rimola
et
al
anoth
report
publish
letterform
describ
outcom
patient
hepat
c
treat
lowdos
interferon
ifn
alpha
iu
time
week
month
combin
ace
inhibitor
perindopril
treatment
accompani
signific
improv
serum
marker
fibrosi
hyaluron
acid
type
iv
collagen
procollagen
iiinpeptid
howev
histolog
analysi
perform
unfortun
imposs
determin
studi
whether
observ
effect
due
perindopril
perindopril
monotherapi
group
includ
yoshiji
noguchi
fukui
final
retrospect
review
compar
liver
histolog
liver
transplant
patient
recurr
hepat
c
take
ra
block
drug
show
group
take
ra
blocker
less
like
develop
sever
hepat
fibrosi
bridg
fibrosi
cirrhosi
year
post
transplant
compar
control
group
vs
year
p
vs
year
p
respect
rimola
recent
studi
provid
clear
evid
hepat
ra
may
major
import
pathogenesi
chronic
liver
diseas
system
upregul
chronic
liver
injuri
contribut
oxid
stress
recruit
inflammatori
cell
develop
fibrosi
ra
also
play
role
pathogenesi
portal
hypertens
mani
system
complic
cirrhosi
ampl
evid
invitro
studi
work
number
anim
model
liver
diseas
suggest
blockad
ra
amelior
liver
injuri
inhibit
hepat
fibrosi
lower
portal
pressur
whilst
ace
inhibitor
arb
proven
invalu
pharmacolog
tool
studi
employ
higher
dose
drug
use
clinic
remain
determin
whether
ra
inhibit
prove
effect
therapeut
approach
treatment
prevent
hepat
fibrosi
complic
human
liver
diseas
fernand
l
fort
zb
nigro
tost
rc
santo
ra
catelli
de
carvalho
mh
potenti
